Compare NKSH & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKSH | ANIK |
|---|---|---|
| Founded | 1891 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 198.9M |
| IPO Year | 1995 | 1996 |
| Metric | NKSH | ANIK |
|---|---|---|
| Price | $35.21 | $14.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 31.7K | ★ 72.8K |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 100.81 | 80.16 |
| EPS | ★ 0.78 | N/A |
| Revenue | $8,176,000.00 | ★ $112,819,000.00 |
| Revenue This Year | N/A | $5.98 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | $45.01 | ★ N/A |
| Revenue Growth | ★ 9.39 | N/A |
| 52 Week Low | $24.74 | $7.90 |
| 52 Week High | $40.00 | $16.24 |
| Indicator | NKSH | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 47.12 |
| Support Level | $35.09 | $13.95 |
| Resistance Level | $38.24 | $15.01 |
| Average True Range (ATR) | 1.02 | 0.56 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 26.13 | 23.32 |
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.